Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07670611

Vitamin D2 vs Vitamin D2 Plus Calcitriol in Cholestatic Children With Vitamin D Deficiency

The goal of this clinical trial is to learn whether adding calcitriol to vitamin D2 can improve vitamin D deficiency in children with cholestasis and chronic liver disease. Cholestasis is a condition in which bile flow is reduced, which can make it difficult for the body to absorb and process vitamin D. The study will also learn about the safety of using vitamin D2 together with calcitriol.

The main questions it aims to answer are:

* Does vitamin D2 plus calcitriol increase blood 25-hydroxyvitamin D (25-OHD) levels more than vitamin D2 alone after 3 months of treatment? * Does vitamin D2 plus calcitriol help more children reach an adequate vitamin D level by 3 and 6 months? * What medical problems, especially high calcium or high phosphorus levels, occur during treatment?

Researchers will compare children who receive vitamin D2 alone with children who receive vitamin D2 plus calcitriol to see which treatment improves vitamin D levels more effectively and safely.

Participants will:

* Take vitamin D2 alone or vitamin D2 plus calcitriol as assigned by randomization * Visit the clinic for study assessments at the start of the study, at 3 months, and at 6 months * Have blood tests to measure vitamin D levels, calcium, phosphorus, parathyroid hormone, liver function, and other safety markers * Have their treatment reviewed at 3 months; participants whose vitamin D level remains low may have their treatment adjusted according to the study plan * Bring back medication packages so researchers can check how regularly the study medicines were taken

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cholestatic Liver Disease Avitaminosis Bile Duct Diseases Biliary Tract Diseases Children Cholestasis Chronic Liver Disease (CLD) Deficiency Diseases Digestive System Diseases Malnutrition Nutrition Disorders Nutritional and Metabolic Diseases Vitamin D Deficiency

Age range

Up to 18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

King Chulalongkorn Memorial Hospital

Bangkok, 10330, Thailand

Location status: Recruiting

Location contact

King Chulalongkorn Memorial Hospital

CONTACT

[email protected]

6622564493

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients younger than 18 years of age.
  • Patients diagnosed with cholestasis, defined as direct/conjugated bilirubin >1 mg/dL for more than 1 month.
  • Patients diagnosed with chronic liver disease.
  • Patients with vitamin D deficiency, defined as serum 25-hydroxyvitamin D (25-OHD) level <20 ng/mL, according to the Endocrine Society Clinical Practice Guideline.

Exclusion criteria

  • Pre-existing hypercalciuria, screened by urine calcium testing before enrollment.
  • Patients with benign or malignant tumors.
  • Patients with renal tubular defects, screened by electrolyte testing before enrollment.
  • Patients currently receiving anticonvulsant therapy.
  • Patients who do not attend scheduled follow-up visits.

Treatment and study plan

Vitamin D2

Drug

Vitamin D2 40,000 IU/week weekly

calcitriol

Drug

Calcitriol 50 ng/kg/day once daily

Primary outcomes

  1. Change From Baseline in Serum 25-Hydroxyvitamin D Concentration at Month 3

    Time frame: Baseline and Month 3

    Change from baseline in serum 25-hydroxyvitamin D [25(OH)D] concentration, measured in ng/mL, at 3 months after treatment initiation. The change will be calculated as the Month 3 value minus the baseline value and compared between treatment groups.

Secondary outcomes

  1. Number of Participants With Correction of Vitamin D Deficiency at Month 3

    Time frame: Month 3

    Number and percentage of participants with serum 25-hydroxyvitamin D [25(OH)D] concentration greater than or equal to 20 ng/mL at Month 3.

  2. Number of Participants With Correction of Vitamin D Deficiency at Month 6

    Time frame: Month 6

    Number and percentage of participants with serum 25-hydroxyvitamin D [25(OH)D] concentration greater than or equal to 20 ng/mL at Month 6.

  3. Change in Serum 25-Hydroxyvitamin D Level From Baseline to Month 6

    Time frame: Baseline to Month 6

    Change in serum 25-hydroxyvitamin D (25-OHD) level, measured in ng/mL, from baseline to 6 months after treatment initiation.

  4. Change From Baseline in Serum Parathyroid Hormone Concentration at Month 3 and Month 6

    Time frame: Baseline, Month 3, and Month 6

    Change from baseline in serum parathyroid hormone concentration, measured in pg/mL, at Month 3 and Month 6. The change will be calculated as the follow-up value minus the baseline value.

  5. Change From Baseline in Serum 1,25-Dihydroxyvitamin D Concentration at Month 3 and Month 6

    Time frame: baseline , Month 3, Month 6

    Change from baseline in serum 1,25-dihydroxyvitamin D concentration, measured in pg/mL, at Month 3 and Month 6. The change will be calculated as the follow-up value minus the baseline value.

  6. Number of Participants With Hypercalcemia During the 6-Month Study Period

    Time frame: Baseline to Month 6

    Number and percentage of participants who develop hypercalcemia during the 6-month study period. Hypercalcemia is defined as albumin-corrected serum calcium above the age-specific upper limit of normal according to the study laboratory reference range.

  7. Change From Baseline in Pediatric End-Stage Liver Disease Score at Month 3 and Month 6

    Time frame: Baseline, Month 3, and Month 6

    Change from baseline in the Pediatric End-Stage Liver Disease (PELD) score at Month 3 and Month 6. The PELD score is calculated using serum bilirubin, international normalized ratio, serum albumin, age less than 1 year, and growth failure. The PELD score has no fixed absolute minimum or maximum possible value and may range from negative to positive values. Higher scores indicate more severe liver disease and a higher risk of short-term mortality/transplant priority.

  8. Change From Baseline in Serum Alanine Aminotransferase Concentration at Month 3 and Month 6

    Time frame: Baseline, Month 3, and Month 6

    Change from baseline in serum alanine aminotransferase (ALT) concentration, measured in U/L, at Month 3 and Month 6. The change will be calculated as the follow-up value minus the baseline value.

  9. Change From Baseline in Serum Aspartate Aminotransferase Concentration at Month 3 and Month 6

    Time frame: Baseline, Month 3, and Month 6

    Change from baseline in serum aspartate aminotransferase (AST) concentration, measured in U/L, at Month 3 and Month 6. The change will be calculated as the follow-up value minus the baseline value.

  10. Change From Baseline in Serum Alkaline Phosphatase Concentration at Month 3 and Month 6

    Time frame: Baseline, Month 3, and Month 6

    Change from baseline in serum alkaline phosphatase concentration, measured in U/L, at Month 3 and Month 6. The change will be calculated as the follow-up value minus the baseline value.

  11. Change From Baseline in Serum Total Bilirubin Concentration at Month 3 and Month 6

    Time frame: Baseline, Month 3, and Month 6

    Change from baseline in serum total bilirubin concentration, measured in mg/dL, at Month 3 and Month 6. The change will be calculated as the follow-up value minus the baseline value.

  12. Change From Baseline in Serum Direct Bilirubin Concentration at Month 3 and Month 6

    Time frame: Baseline, Month 3, and Month 6

    Change from baseline in serum direct bilirubin concentration, measured in mg/dL, at Month 3 and Month 6. The change will be calculated as the follow-up value minus the baseline value.

  13. Change From Baseline in International Normalized Ratio at Month 3 and Month 6

    Time frame: Baseline, Month 3, and Month 6

    Change from baseline in international normalized ratio (INR) at Month 3 and Month 6. The change will be calculated as the follow-up value minus the baseline value. Higher INR values indicate worse coagulation function.

  14. Change From Baseline in Serum Albumin Concentration at Month 3 and Month 6

    Time frame: Baseline, Month 3, and Month 6

    Change from baseline in Serum Albumin Concentration at Month 3 and Month 6. The change will be calculated as the follow-up value minus the baseline value. Lower serum albumin values indicate worse hepatic synthetic function.

Study contacts

Contact information is provided by the study sponsor or research team.

THANAPORN NiLYAEM

CONTACT

[email protected]

66852811244

Sponsors and collaborators

Lead sponsor

Chulalongkorn University

Other

Registry information

Official study title

Accelerated Correction of Vitamin D Deficiency in Cholestatic Children: a Comparative Trial of Vitamin D2 Monotherapy vs Combination Therapy With Calcitriol

Acronym: VITD-CHOL

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Jun 26, 2026
Registry last updated
Jul 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.